Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK

Ravindhi Murphy,Gurvin Chander,Maria Martinez,Caroline Ward,Sairah R Khan,Mitesh Naik,Tara Barwick,Eric Aboagye,Rohini Sharma

doi:10.1136/bmjopen-2023-075221

Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK

Ravindhi Murphy, Gurvin Chander + Show 7 more

Open Access

https://doi.org/10.1136/bmjopen-2023-075221

Copy DOI

Journal: BMJ open	Publication Date: Oct 1, 2023
License type: CC BY-NC 4.0

Affiliation: Hammersmith Hospital, Birmingham Women’s and Children’s NHS Foundation Trust, Imperial College London, Imperial College Healthcare NHS Trust

#Peptide Receptor Radionuclide Therapy #Metastatic Neuroendocrine Tumours + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionSuitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by [68Ga]Ga-DOTA-peptide-positron emission tomography (PET). Some patients have low or no...

Full Text